Key takeaways
Tagrisso (osimertinib) and Keytruda (pembrolizumab) are both medications used to treat non-small cell lung cancer (NSCLC), but they belong to different medication classes and work in distinct ways. Tagrisso is an epidermal growth factor receptor (EGFR) inhibitor, taken orally, that targets specific mutations in the EGFR gene to stop cancer cells from growing. Keytruda, on the other hand, is a programmed death-1 (PD-1) pathway inhibitor given as an intravenous infusion, which helps your immune system recognize and attack cancer cells. While Tagrisso is specifically approved for NSCLC with certain EGFR mutations, Keytruda is used for a broader range of cancers, including NSCLC, melanoma, and breast cancer, among many others. Tagrisso is typically taken once daily, whereas Keytruda is administered every 3 or 6 weeks, depending on your treatment plan. Common side effects of Tagrisso include an acne-like rash and diarrhea, while Keytruda can cause immune-related side effects like high blood sugar, rash, and trouble breathing. Both medications have potential risks during pregnancy, so effective birth control is recommended while taking them.
